Kazia Therapeutics Ltd
Kazia Therapeutics Ltd (ASX:KZA) is listed on the Australian Securities Exchange.
Related news
- Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma
2020-09-22 - Kazia Therapeutics bringing a vetted drug class to the brain: Edison
2020-09-09 - Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma
2020-08-24 - Kazia Therapeutics raises $1.8 million in well supported share placement
2020-05-06 - Kazia Therapeutics extends SPP owing to strong demand
2020-05-04 - Kazia Therapeutics substantial holder increases position
2020-03-19 - Kazia Therapeutics finishes trial enrolment, sets date for data release
2020-03-06 - Kazia Therapeutics to join international study in glioblastoma with lead program GDC-0084
2019-12-11 - Kazia Therapeutics shares surge after positive early phase II study results for GDC-0084 in brain cancer patients
2019-11-25 - Kazia Therapeutics raises $4 million to progress R&D programs
2019-10-28 - Kazia Therapeutics presents ovarian cancer study at conference
2019-09-30 - Kazia Therapeutics wins ANZLF Trans-Tasman Innovation and Growth award
2019-09-13 - Kazia Therapeutics designated name for brain cancer drug by World Health Organisation
2019-08-23 - Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study
2019-08-13 - Kazia Therapeutics studies evaluate therapeutic candidates in ovarian cancer and brain tumours
2019-05-02 - Kazia Therapeutics will outline anti-cancer drug development strategy at CEO Sessions
2019-02-07 - Kazia Therapeutics progresses phase II clinical trial for brain cancer drug
2018-03-29
